Gene Virus

基因和病毒治疗计划（GVTP）目前由12名成员组成，包括基础科学家和 来自八个部门和部门的临床研究人员互动合作，开发新的， 以基因为基础的癌症治疗方法。该计划的目标是：（1）提高 了解用于创建新基因递送系统的病毒和细胞的生物学;（2） 推进新的基因和病毒疗法的技术基础;（3） 通过开发新的基于基因和病毒的疗法和测试来改善癌症治疗的结果 他们在诊所。主要研究主题为（I）临床前和临床药理学;（II）载体 靶向;（III）细胞载体;和（IV）免疫调节。方案内的互动十分密集， 包括多个合作，定期业务教师会议，并在科学交流， 定期举办期刊俱乐部和方案研讨会。方案间的实质性互动， 临床翻译过程中必不可少的，已经建立了基因和病毒治疗之间的关系， 计划，免疫学和免疫治疗计划，血液肿瘤计划， 妇女癌症项目、胃肠道癌症项目和神经肿瘤项目。的 基因和病毒治疗计划受益于斯蒂芬罗素，医学博士，博士，一个强大的领导 在基因和病毒治疗领域具有相当地位的血液学家。美国国立卫生研究院的资金基础 该计划目前每年的总成本为350万美元，其中58%来自国家癌症研究所。 院该计划在当前资助期内的生产力很高， 共有320篇出版物和4项I期临床试验，其中设计了重组病毒， 在马约诊所罗切斯特制造、临床前测试和生产的药物正在用于患有以下疾病的患者： 各种癌症。此外，在翻译管道中有几个非常有前途的项目， 包括罗切斯特的GVTP与 亚利桑那州马约诊所的胃肠道癌症项目，以推进重组溶瘤囊泡 口腔炎病毒对肝癌患者的临床检测。 共320份出版物; 17%方案内; 23%方案间

The Gene & Virus Therapy Program (GVTP) currently comprises twelve members, both basic scientists and clinician investigators from eight departments and divisions working interactively to develop novel, genetically based approaches to the treatment of cancer. The goals of the program are: (1) to enhance understanding of the biology of the viruses and cells that are used to create new gene delivery systems; (2) to advance the technology base from which new gene and virus based therapies can be created; and (3) to improve the outcomes of cancer treatment by developing new gene and virus based therapies and testing them in the clinic. The major research themes are (I) preclinical and clinical pharmacology; (II) vector targeting; (III) cellular carriers; and (IV) imrhunomodulation. Intra-programmatic interactions are intensive, comprising multiple collaborations, regular operational faculty meetings, and scientific exchanges in the context of regular journal clubs and programmatic seminars. Substantive inter-programmatic interactions, essential for the process of clinical translation, have been established between the Gene & Virus Therapy Program, the Immunology & Immunotherapy Program, the Hematologic Malignancies Program, the Women's Cancer Program, the Gastrointestinal Cancer Program, and the Neuro-oncology Program. The Gene & Virus Therapy Program benefits from the strong leadership of Stephen Russell, MD, PhD, a hematologist with considerable stature in the field of gene and virus therapy. The NIH funding base for this program currently stands at $3.5 million per annum in total costs of which 58% is from the National Cancer Institute. Productivity of the program during the current funding period has been substantial, amounting to a total of 320 publications and four Phase I clinical trials in which recombinant viruses that were designed, built, preclinically tested, and manufactured at Mayo Clinic Rochester are being administered to patients with various types of cancer. Additionally, there are several very promising projects in the translational pipeline, including a major inter-programmatic collaboration between the GVTP in Rochester and members of the Gastrointestinal Cancer Program in Mayo Clinic Arizona to advance a recombinant oncolytic vesicular stomatitis virus to clinical testing in patients with hepatocellular carcinoma. 320 total publications; 17% intra-programmatic; 23% inter-programmatic